In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure (Apr 2020)
Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives (Feb 2017)